CRISPR Editing of HBG1/HBG2 to Increase Fetal Hemoglobin
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemoglobinopathies such as sickle cell disease and beta-thalassemia are inadequate, with methods like gene therapy and stem cell transplantation posing risks and challenges in efficacy and donor matching.
Innovation Solution
Genome editing systems using CRISPR-mediated methods and guide RNAs to alter gamma-globin genes (HBG1, HBG2) and the BCL11A gene, increasing fetal hemoglobin expression by unwinding chromatin with RNA-guided helicases and dead guide RNAs to enhance accessibility for nucleases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current gene therapy methods are used to treat hemoglobinopathies, then treatment efficacy is improved, but the risk of adverse events and complexity of the treatment process increases
Solution Approach 1:
The treatment approach segments the complex process into distinct phases: (1) ex vivo genome editing of hematopoietic stem cells using CRISPR-Cas9 to disrupt BCL11A or HBG1/2 genes, (2) selective expansion of edited cells in culture, and (3) autologous transplantation back into the patient. This segmentation allows each phase to be optimized independently and reduces overall treatment complexity.
Solution Approach 2:
The therapy utilizes the patient's own hematopoietic stem cells that are edited in vitro and then reinfused, creating a self-service treatment model where the patient's own cells perform the therapeutic function. This eliminates the need for donor matching and reduces the complexity of allogeneic transplantation protocols.
2Reliability
If stem cell transplantation is used to treat hemoglobinopathies, then disease cure is achieved, but donor matching requirements and treatment risks increase
Solution Approach 1:
The therapy uses autologous hematopoietic stem cells from the patient themselves, edited ex vivo, eliminating the need for donor matching. The patient's own HSCs are modified to produce functional hemoglobin and then reinfused, creating a self-sufficient treatment that does not depend on finding a compatible donor.
Solution Approach 2:
The therapy extracts and modifies the therapeutic function from the donor cell context and implants it into the patient's own cells through ex vivo editing. By taking the editing machinery out of the in vivo setting and performing it in vitro, the need for donor cells is eliminated.
3Reliability
If CRISPR-mediated genome editing is used to alter gamma-globin genes, then fetal hemoglobin expression is increased, but the complexity of guide RNA design and target site selection increases
Solution Approach 1:
The therapy targets specific local regions in the genome (the BCL11A erythroid enhancer or the HBG1/2 promoter regions) with high precision guide RNAs. By focusing the editing activity on these specific loci rather than the entire genome, the complexity of guide RNA design is managed through targeted rather than comprehensive targeting.
Solution Approach 2:
The guide RNAs and Cas9 enzymes are designed and prepared in advance before cell processing. The target sites are identified and validated beforehand, allowing the actual editing to proceed efficiently once the cells are ready. This preliminary preparation reduces the complexity during the critical treatment phases.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Increases fetal hemoglobin levels in erythroid cells, potentially reducing disease symptoms and improving patient outcomes by altering target nucleic acid sequences and modulating gene expression.
Implementation Method 1
unwinding chromatin with RNA-guided helicases and dead guide RNAs to enhance accessibility for nucleases
Implementation Method 2
CRISPR-mediated methods and guide RNAs to alter gamma-globin genes
Data Source
AI summary
Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci in cells and increasing expression of fetal hemoglobin.